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Abstract Gastrin-releasing peptide (GRP) receptors are
over-expressed in various human tumor including breast
and prostate which can be targeted with bombesin for
diagnosis and targeted therapy. High abdominal accumu-
lation and the poor in vivo stability of radiolabeled bom-
besin analogues may represent a limitation for diagnostic
imaging and targeted therapy. In this study a new bombesin
derivative was labeled with 99mTc via HYNIC and tricine
as a coligand and investigated further. The peptide HYNIC
conjugate was synthesized on a solid phase using Fmoc
strategy. Labeling with 99mTc was performed at 100 C for
10 min and radiochemical analysis involved ITLC and
HPLC methods. The stability of radiopeptide was checked
in the presence of human serum at 37 C up to 24 h.
Internalization was studied with the human GRP receptor
cell line PC-3. The Biodistribution was studied in mice.
Labeling yield of [98 % was obtained to correspond a
specific activity of *80.9 GBq/lmol. Radioconjugate
internalization into PC-3 cells was high and specific
(15.6 ± 1.9 % at 4 h). A high and specific uptake in GRP-
receptor-positive organs such as mouse tumor and pancreas
(2.11 ± 0.18 and 1.78 ± 0.09 % ID/g after 1 h respec-
tively) was also determined.
Keywords GRP  Bombesin  Tumor 
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Introduction
In recent years, small radiolabeled receptor binding peptides
exhibit a great potential for receptor-imaging and tumor
targeting because of their easy preparation, easy radiola-
beling, rapid clearance from blood, non-target tissues, low
toxicity, low immunogenicity, high affinity and specificity
for receptors [1–3]. Peptide receptors are over-expressed in
various human tumor cells which can be targeted with
peptide-based radiopharmaceuticals for diagnosis and tar-
geted therapy [1–4]. Bombesin (BB), a tetradecapeptide
analogue of human gastrin-releasing peptide (GRP) is one of
the most promising peptides which show high affinity for
GRP receptor. Over-expression of GRP receptors in several
malignant tumors, particularly prostate, lung, breast and
colon cancers which make these receptors promising
molecular targets for radiolabeled BB derivatives [2–8].
High abdominal accumulation and the poor in vivo
stability of radiolabeled BB analogues may represent a
limitation for diagnostic imaging and targeted therapy
[9–12]. A variety of techniques are available concerning the
design and development of new BB derivatives that include
introduction/substitution of specific amino acids, chelating
group and more important spacer chain[8, 11, 13]. All these
agents have influence on radioactivity accumulation in the
abdominal region and tumor/normal organ rations [11, 13].
Among the BB derivatives labeled with various radio-
nuclides, BB (7–14) analogues seem to be one of the most
BB peptides for development and design of new BB
derivatives. It has been shown that the C-terminal region
(Gln7-Trp8-Ala9-Val10-Gly11-His12-leu13-Met14-NH2) of BB
is necessary for retaining receptor binding affinity and its
biological activity [6, 8, 14–18]. Labeling of BB analogues
with 99mTc has been performed either directly or mainly
indirectly via bifunctional chelator agents such as MAG3
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(mercaptoacetyltriglycine), N2S2. DTPA (diethlene-
triaminepentaacetic acid) and HYNIC (2-hydrazinonicoti-
namide) with or without the presence of a linker or spacer
function [5, 6, 8, 11, 15, 16, 19–21]. The HYNIC-biomol-
ecules including antibodies and peptides require coligands
such as tricine and ethylenediamine diacetic acid (EDDA)
for completing the coordination sphere of the technetium
(V) core with allowing easy modification of the hydrophi-
licity and pharmacokinetics [6, 8]. It has been demonstrated
in recent studies that 99mTc-radiolabeling yield of HYNIC-
BB derivatives using tricine as co-ligand and tricine/EDDA
the exchange labeling is high [22–25]. In recent reports,
utilizing various types of spacer chains has demonstrated
that uncharged hydroxyl amino acids and spacer length in
addition reduced kidney uptake resulted in significantly
better tumor-to-tissue ration [2, 11]. Probably proteolysis of
BB derivatives in plasma occur between His12-Leu13 and the
slightly modified of BB derivatives have influence on sta-
bility and receptor binding affinity [11, 13, 26].
We also recently reported the preparation and evaluation
of new 99mTc labeled bombesin derivatives via HYNIC as
a bifunctional chelating agent and tricine as co-ligand and
tricine/EDDA exchange labeling [22–24]. To extend our
previous study and enhance in vivo stability together with
improve tumor targeting and pharmacokinetics character-
istics, we chose a BB (7–14) and (D-Tyr)2 as a spacer to
improve excretion pattern via kidney and modified D-Phe13
versus Leu13 to decrease proteolysis in plasma and increase
biological activity.
Here we present data on the synthesis of [HYNIC-
D-Tyr5-D-Tyr6-D-Phe13] BB (5–14), describe optimum
conditions for radiolabeling with 99mTc using tricine as
coligand and in vitro/in vivo study of the radiolabeled
peptide for targeting GRP receptor-positive tumors.
Experimental
Materials and methods
Rink amide 4-methylbenzhydrylamine (MBHA) resin and
all Fmoc-protected amino acids were obtained from No-
vaBiochem. The prochelator HYNIC-Boc was synthesized
according to Abrams et al. [27]. Other reagents were pur-
chased from Fluka, and used without further purification.
The reactive side chains of the amino acids were masked
with one of the following groups: Trp, t-butoxycarbonyl;
His, trityl; Tyr, t-butyl. The cell culture medium was
Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with 10 % fetal bovine serum (FBS), amino acids,
vitamins and penicillin/streptomycin from Gibco. Sodium
pertechnetate (Na 99mTcO4) obtained from commercial
99Mo/99mTc generator (Radioisotope Division, AEOI).
Analytical reverse phase high performance liquid chro-
matography (RP-HPLC) was performed on a JASCO
880-PU intelligent pump HPLC system equipped with a
multiwavelength detector and a flow-through Raytest–Gabi
c-detector. CC 250/4.6 Nucleosil 120-5 C18 column from
Teknokroma was used for analytical HPLC, and a VP
250/10 Nucleosil 100-5 C18 column was used for semi-
preparative HPLC. The gradient systems consisted of
0.1 % trifluoroacetic acid/water (Solvent A) and acetoni-
trile (Solvent B). For analytic HPLC, Gradient I was used:
0 min 95 % A (5 % B), 5 min 95 % A (5 % B), 30 min
0 % A (100 % B), 33 min 0 % A (100 % B), 35 min 95 %
A (5 % B), flow = 1 ml/min, k = 280 nm. For semipre-
parative HPLC Gradient II was used: 0 min 80 % A (20 %
B), 2 min 80 % A (20 % B), 17 min 50 % A (50 % B),
19 min 0 %A (100 % B), 21 min 0 % A (100 % B),
25 min 80 % A (20 % B) flow = 2 ml/min, k = 280 nm.
Mass spectrum was recorded on a HP 1100 series LC/
MSD. Quantitative gamma counting was performed on an
ORTEC Model 4001 M c-system well counter.
Synthesis
The peptide-chelator conjugate was synthesized by standard
Fmoc solid phase synthesis on Rink Amide MBHA resin with
substitution, 0.69 mmol/g. Coupling of each amino acid was
performed in the presence of 3 mol excess of Fmoc-amino
acid, 3 mol excess of N-hydroxybenzotriazole, 3 mol excess
of Diisopropylcarbodiimide and 5 mol excess of diisopro-
pylethylamine (DIPEA) in dimethylformamide (DMF).
Coupling success was checked by the established 2,4,6-tri-
nitrobenzenesulfonicacid test. Cleavage of the Fmoc group
was achieved by repetitive treatment with 20 % piperidine in
DMF. Coupling of HYNIC to peptide was performed in the
presence of 1.2 mol excess of HYNIC-BOC 2.5 mol excess
of (2-(7-Aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluro-
nium hexafluorophosphate), 5 mol excess of DIPEA in DMF.
The peptide HYNIC conjugate was removed from the resin
and amino acid side chains were deprotected by treatment
with a cocktail of trifluoro acetic acid, triisopropylsilane and
water (95:2.5:2.5). After removing the organic solvents in
vacuo, the crude product was precipitated with cold diethyl
ether. The crude peptide HYNIC conjugate was dissolved in
water and purified by semi-preparative (Gradient II) RP-
HPLC, next the purified product was characterized by LC/
MSD and analytic HPLC.
Radiolabeling with 99mTc
Radiolabeling of peptide HYNIC conjugate was performed
by adding 20 lg (13.9 nmol) of the stock solution new
HYNIC-BB derivative (1 mmol/l in water) and 20 mg
(112 lmol) of tricine co-ligand in 0.5 mL of water. 40 lg
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SnCl2 (20 ll of 2 mg/ml SnCl2, 2H2O in nitrogen-purged
0.1 M HCl) were added to this solution. Finally,
370–1,110 MBq of 99mTcO4
- in 0.5 mL saline was added
to the solution and incubated for 10 min at 100 C.After
cooling down to room temperature, the reaction mixture
was analyzed.
Radiochemical analysis
After cooling up to room temperature, the radiolabeling
yield of the labeled peptide was determined by analytical
RP-HPLC (Gradient I) and ITLC on silica gel 60 (Merck)
using different mobile phases: 2-butanone for free 99mTcO4
(Rf = 1), 0.1 M sodium citrate (pH 5) to determine the
non-peptide bound 99mTc coligand with 99mTcO4 (Rf = 1)
and methanol/1 M ammonium acetate 1/1 for 99mTc colloid
(Rf = 0). The radioactivity was quantified by cutting the
strip (1.5 9 10 cm2) into 1 cm pieces and counting in a
well type gamma counter.
Human serum stability
To 1 mL of freshly prepared human serum, we added 100 ll
(14.8–29.6 MBq) radiolabeled BB derivative and mixture
was incubated at 37 C. 100 ll aliquots was removed and
treated with 200 ll of ethanol [11] at different times up to
24 h. Sample was centrifuged at 3,000 rpm for 15 min to
precipitate serum proteins. The supernatant was filtered
through a 0.20 lm pore filter and analyzed with RP-HPLC
Gradient I to determine radiochemical stability.
Cell culture
The human androgen-independent prostate carcinoma cell
line PC-3 was obtained from National Cell Bank of Iran
(NCBI) affiliated to Pasteur Institute of Iran. The cells
were grown in DMEM supplemented with 10 % (v/v) fetal
bovine serum (FBS), 1 % L-glutamine (2 mM),1 % penicil-
lin(100 IU/ml)/streptomycin(100 lg/ml) and 1 % amphoter-
icin B(0.25 lg/ml). The cells were incubated at 37 C in a
humidified atmosphere containing 5 % CO2 and were sub-
cultured weekly detaching with trypsin/EDTA solution
(0.25 %).
Internalization assay
Medium was removed from the 6-well plates contain PC-3
cells with density of 1 million cells per well and cells were
washed once with 2 ml of internalization medium (DMEM
with 1 % FBS). Furthermore, 1.5 ml internalization medium
was added to each well, and the plates were incubated at 37 C
for about 1 h. Afterwards, about 150 kBq (2.5 pmol total
peptide mass per well) was added to the medium, and the cells
were incubated at 37 C for various time periods. To deter-
mine nonspecific internalization, we incubated cells with the
radioligand in the presence of 150 ll, 1 lmol/l Bombesin.
The cellular uptake was stopped at appropriate time periods
(30 min, 1 h, 2 h and 4 h) by removing medium from the cells
and washing twice with 1 ml of ice-cold phosphate-buffered
saline (PBS). An acid wash for 10 min with a glycine buffer
(pH 2.8) on ice was also performed twice. This step was to
distinguish between membrane-bound (acid releasable) and
internalized (acid resistant) radioligand. Finally, the cells were
treated with 1 N NaOH. The culture medium, the receptor-
bound and internalized fractions were measured radiometri-
cally in a gamma counter.
Biodistribution
Animal experiments were performed in compliance with
the regulations of our institution and with generally
accepted guidelines governing such a work. A suspension
of human PC-3 cells (1 9 107) in PBS buffer was subcu-
taneously injected in the right flank of each nude mouse.
Seven to 10 days after inoculation, the tumors were
inducted and then an activity of 20 MBq (0.35 nmol) of
99mTc-Bombesin was injected via the femoral vein. In
order to determine the non-specific uptake of the radio-
peptides, in receptor-positive organs, a group of 3 animals
were injected with 100 lg cold peptide in 50 ll saline as a
co-injection with the radiopeptides (blocked animals).
After 1, 4 and 24 h, the mice in groups of 3 animals were
scarified, organs of interest were collected, weighed and
radioactivity was measured in a gamma counter. The per-
centage of the injected dose per gram (% ID/g) was cal-
culated for each tissue.
Statistical analyses
The calculations of means and standard deviations for
internalization and biodistribution were performed on
Microsoft Excel. Student’s t test was used to determine
statistical significance. Differences at the 95 % confidence
level (P \ 0.05) were considered significant.
Results
Synthesis
[HYNIC-D-Tyr5-D-Tyr6-D-Phe13] BB (5–14) (Fig. 1) was
synthesized by Fmoc strategy supplying an overall yield of
nearly 47 %. The composition and structural identity of
HYNIC peptide was verified by LC-MSD (Table 1). The
chemical purity was [99 % as confirmed by RP-HPLC
method.
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Radiolabling
The radiochemical yield of [99mTc/tricine/HYNIC0, D-Tyr5-
D-Tyr6-D-Phe13] Bombesin (5–14) NH2, was higher than
98 % by HPLC and also ITLC at a specific activity of
81 GBq/lmol. The HPLC elution time (gradient I) were
19.20 min for 99mTc-peptide and 5.72 min for 99mTcO4
(Fig. 2).
Internalization assay and stability
The result of the in vitro assay of the radioligand into PC-3
cell showed fast receptor-specific internalization (5.3 ±
1.1 % at 1 h and 15.6 ± 2.3 % at 4 h). As it shows the
significant differences of uptake between blocked and un-
blocked cells in various time periods are very noticeable
(P \ 0.05) (Fig. 3). After 24 h in human serum, the








































Fig. 1 Structure of [HYNIC-D-Tyr5-D-Tyr6-D-Phe13] BB (5–14)
Table 1 Data for [HYNIC0, D-Tyr6, D-Trp8]-BZ [6–14] NH2 from
LC/MSD analysis
Compound Calculated mass (g) Observed mass (g)
[HYNIC]-peptide 1434.61 1435.09 [M?H]?;100 %
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Animal biodistribution studies
Figure 4 shows the results of biodistribution studies. Ra-
diopeptide exhibited a rapid clearance from the blood with
0.19 ± 0.06 % after 4 h. There was also fast clearance
from the GRP receptor-negative tissues with predominantly
renal excretion. New 99mTc labeled BB derivative showed
a high uptake of radioactivity in the PC-3 tumor and in the
GRP receptor-positive organs such as the pancreas. By
blocking the receptor through prior injection of cold pep-
tide, the uptake in tumor and pancreas is diminished and
this confirms the specificity of radioconjugate. Reduction
uptake percentages were 82 % (1.32 vs. 0.24 % ID/g,
P \ 0.05) and 76 % (0.93 vs. 0.22 % ID/g, P \ 0.05)
respectively (Table 2). On the other hand, the uptake
reduction in non-targeted tissues due to the blocking dose
was not significantly.
Discussion
Peptide sequences influence on tumor uptake, in vivo stability,
pharmacokinetic characteristics, binding affinity for the
receptors and the coordination of 99mTc by HYNIC peptide
conjugate [11, 13, 25, 28]. If 99mTc-HYNIC peptide becomes
more stable, then it may result in improved tumor targeting and
body retention. On the other hand, a change in configuration
would be likely to reduce the performance of the radiophar-
maceutical in vivo. HYNIC makes labeling with 99mTc in high
specific activity possible followed by using various coligands,
which permit control of the hydrophilicity and pharmacoki-
netics of the labeled peptide [6, 22–25, 28]. High specific
activity achieves with low concentration of the HYNIC pep-
tide conjugate. One of the most widely used coligands is tri-
cine. Tricine gives the best radiolabeling efficiency but it has
been reported that tricine as a coligand, 99mTc-complex was
not stable, particularly in dilute solutions, due to different
bonding modalities of the hydrazine moiety of the HYNIC and
the tricine coligand [6, 25, 28]. As we have previously shown
that bombesin derivative [HYNIC-D-Tyr6-D-Trp8] BB (6–14)
is as potential targeted tumor imaging agent [22, 23]. There-
fore we extended our pervious study with a new radiolabeled
bombesin derivative with sequences bombesin (7–14),
D-Phe13 versus leu13 modification and (D-Tyr)2 as spacer to
improve excretion pattern via kidney, improve binding affinity
and to decrease enzymatic metabolism. In this study we used
HYNIC peptide with tricine as a coligand in amounts of 20 lg
and 20 mg in final volume of labeled solution respectively. We
obtained high radiochemical yield ([98 %) with very low
amount of 99mTc-pertechnetate (\0.5 %), 99mTc-radiocolloid
(\1 %) and 99mTc-coligand (\0.3 %). In RP-HPLC analysis,
we observed a single major peak without any impurities due to


























Fig. 3 Time course internalization of [99mTc/tricine/HYNIC0,
D-Tyr5-D-Tyr6-D-Phe13] bombesin (5–14) in unblocked and blocked
PC-3 cells. Result of three independent experiments with triplicates in
each experiment
Fig. 4 Biodistribution findings in mice (% injected dose per gram
organ ± SD, n = 3)
Table 2 Biodistribution in mice (% injected dose per gram
organ ± SD, n = 3) 4 h after administration [99mTc/tricine/HYNIC0,
D-Tyr5-D-Tyr6-D-Phe13] Bombesin (5–14)
Organ Unblocked Block
Blood 0.19 ± 0.06 0.21 ± 0.08
Bone 0.11 ± 0.05 0.14 ± 0.02
Kidneys 3.65 ± 1.12 3.85 ± 1.7
Pancreas 0.93 ± 0.17 0. 22 ± 0.12
Spleen 0.14 ± 0.06 0.17 ± 0.09
Stomach 0. 13 ± 0.03 0.11 ± 0.03
Intestines 0.96 ± 0.44 1.2 ± 0.21
Liver 0.15 ± 0.08 0.17 ± 0.04
Lung 0.23 ± 0.04 0.28 ± 0.07
Heart 0.15 ± 0.02 0.16 ± 0.02
Muscle 0.06 ± 0.02 0.07 ± 0.03
PC-3 tumor 1.32 ± 0.08 0.24 ± 0.05
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comparison to those reports regarding 99mTc-tricine-HYNIC
complex instability [28, 29], our new labeled peptide conju-
gate was stable up to a 24 h post labeling period in the room
temperature. These high labeling yield and stability may be
due to optimization of condition in amount of materials,
Peptide sequence and also in our labeling method.
Radiotracer showed internalization profile with
increased value from 0.5 h (2.3 ± 0.9 %) to 4 h
(15.6 ± 1.9 %) incubation time. The efflux rate of radio-
peptide from PC-3 tumor cell after 4 h showed an
acceptable intercellular trapping. Pervious works of BB
derivatives also demonstrate internalization and receptor
mediated trapping of labeled compounds [4, 21]. Compare
with our pervious compound [99mTc-tricine-HYNIC0-
D-Tyr6-D-Trp8] BB (6–14) [22, 23], this new derivative
showed higher rate of internalization after 4 h in PC-3
(15.6 ± 1.9 vs. 10.7 ± 1.2 %).It could be due to D-Phe13
versus leu13 modification and replacement of (D-Tyr)2 as
spacer instead of D-Tyr6. As liolios et al. [11] reported that
the incorporation of positively and negatively charged the
amino acid spacer decrease the binding affinity of the BB
analogue for GRP receptor. In the present study, it seems
that uncharged the amino acid composed from tyrosine
increases binding affinity of new BB analogue.
The results of biodistribution showed fast blood clear-
ance of radiopeptide with \0.19 % ID/g and rapid excre-
tion performed mainly by renal pathway at 4 h. In addition,
in vivo studies exhibited low abdominal accumulation and
significant and specific uptake of radioconjugate in tumor
and pancreas. The highest non-specific uptake was found in
kidneys. A significant uptake of radioactivity was observed
in the pancreas which expresses GRP receptors. The
specificity of radioconjugate was confirmed by blocking
the receptor through prior injection of cold peptide.
Garayoa et al. [30] reported that uncharged hydroxyl linker
as serine improved the biodistribution and resulting in increase
in the tumor uptake. Compare with our pervious study [22, 23]
the uptake of radiopeptide in tumor and pancreas increased
(2.11 vs. 1.12 % ID/g, P \ 0.05 and 1.78 vs. 1.04 % ID/g,
P \ 0.05 at 1 h) respectively. These results indicate that the
charge in linker might be a key factor for determining the
pharmacological characteristics of BB derivatives. As the most
of BB derivatives exhibit high abdominal accumulation which
may represent a problem in their clinical for diagnostic
imaging and targeted therapy [12]. Our compound with mod-
ified lipophilicity has a good improvement in renal excretion,
significant and specific tumor uptake.
Conclusions
In general, this study performed for new [HYNIC-D-Tyr5-
D-Tyr6-D-Phe13] BB (5–14) derivative showed that
hydrophilicity, charge of spacer and sequence of peptide influ-
enced on the bidistribution and the affinity. In this study, labeling
of [HYNIC-D-Tyr5-D-Tyr6-D-Phe13] BB (5–14) with 99mTc was
completed within a very short time by using tricine coligand in
high specific activity (*80.9 GBq/lmol) which makes it an
ideal conjugate for usage in clinical nuclear medicine laborato-
ries. Furthermore, this labeled peptide conjugate demonstrated
excellent radiochemical stability even up to 24 h post labeling.
Our new radiopeptide had a specific cell binding and internali-
zation followed by a good stability in human serum at 37 C for
at least 24 h and no significant impurities were detected by
HPLC. The prepared radiopeptide showed a high accumulation
of radioactivity in tumor and pancreas as a positive GRP
receptors targeted tissue followed by excretion via the kidneys.
These promising Characteristics make our new designed labeled
peptide conjugate as a very suitable candidate for diagnostic
imaging of GRP receptor-positive tumors.
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